First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF; Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients with EGFR-Driven Advanced Solid Tumors
For more information about the trial above please contact the study team:
Principal Investigator, John Kaczmar, at email@example.com, or please call +1 843-792-6691.
Study Coordinator, Carly Fecio, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina